<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>930</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11121543</PubmedId>
            <Abstract>In the present work we demonstrate the application of a commercial biosensor instrument (BIACORE 1000, Biacore AB, Uppsala) for the detection of antibodies against the hepatitis A virus (HAV) in human serum samples using linear and branched synthetic peptides related to the VP3 capsid protein of HAV. We also studied the conformation of the synthetic peptides by circular dichroism (CD) in order to analyse the changes in secondary structure of the constructs that could influence their recognition by antibodies. Linear and dimeric VP3(110-121) multiple antigen peptides (MAP) were the most sensitive and appropriate for serological studies of serum from HAV infected patients using BIACORE. Immobilization of tetrameric MAPs via amine groups apparently failed to preserve the active conformation of the peptide epitope since it led to lower antibody binding compared to linear and dimeric peptides. The CD analysis showed that the tetrameric MAP constructs tend to adopt a beta-sheet structure due to intermolecular aggregation, which limits epitope accessibility. Our results demonstrate the value of biospecific interaction analysis technology using synthetic peptides for the diagnosis of acute hepatitis A.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>13-24</ArticlePages>
            <ArticleTitle>Assessment of synthetic peptides for hepatitis A diagnosis using biosensor technology.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gómara</LastName>
                    <ForeName>M J</ForeName>
                </Author>
                <Author>
                    <LastName>Ercilla</LastName>
                    <ForeName>G</ForeName>
                </Author>
                <Author>
                    <LastName>Alsina</LastName>
                    <ForeName>M A</ForeName>
                </Author>
                <Author>
                    <LastName>Haro</LastName>
                    <ForeName>I</ForeName>
                </Author>
            </Authors>
            <Affiliations>Departament de Química de Pèptids i Proteïnes, IIQAB-CSIC, Jordi Girona 18-26, 08034, Barcelona, Spain.</Affiliations>
            <ArticleChemicalList>Capsid Proteins;Hepatitis A Antibodies;Hepatitis Antibodies;Oligopeptides;Peptide Fragments;VP3 peptide (110-121), hepatitis A virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Antibody Specificity; Antigen-Antibody Reactions; Biosensing Techniques(methods); Capsid(chemistry; immunology; metabolism); Capsid Proteins; Circular Dichroism; Enzyme-Linked Immunosorbent Assay; Hepatitis A(blood; diagnosis; immunology); Hepatitis A Antibodies; Hepatitis Antibodies(blood); Humans; Molecular Sequence Data; Oligopeptides(chemistry; immunology; metabolism); Peptide Fragments(chemistry; immunology; metabolism); Protein Conformation; Protein Structure, Secondary; Reproducibility of Results; Sensitivity and Specificity</ArticleMeshHeadingsList>
            <Journal>
                <Volume>246</Volume>
                <Issue>1-2</Issue>
                <Title>Journal of immunological methods</Title>
                <Issn>0022-1759</Issn>
                <MedlineTa>J Immunol Methods</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>VP3 (110-121)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                        <StartingPosition>110</StartingPosition>
                        <EndingPosition>121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAR01186.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12092</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1</LocationOfData>
                <EpitopeId>18363</EpitopeId>
                <ReferenceStartingPosition>110</ReferenceStartingPosition>
                <ReferenceEndingPosition>121</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>10663</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>159</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>25</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>22</NumberOfSubjectsResponded>
                            <ResponseFrequency>88</ResponseFrequency>
                            <AssayComments>Using a  linear form of the epitope, a 88% sensitivity is obtained for detection of anti-hepatitis Abs in infected individuals. Positive threshold is considered as 2SD above the media signal from 10 normal human sera. The specificity of the signal is shown to be high, and a good correlation between ELISA and SPR analysis. Similar results were obtained with a dimeric epitope construct, while the use of a tetrameric form yielded less sensitivity, which is attributed to interchain aggregation on the biosensor chip due to its high content of beta-sheet structure. Soluble forms are able to compete the binding of linear forms more effectively than the linear forms themselves.  The peptide was immobilized in a biosensor chip and 100 microliters 1/100 diluted individual sera was added to the chip at a 10 microliter /min flow rate.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP3 (110-121)</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01186.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>10666</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:12549</DiseaseState>
                                <DiseaseStage>Acute/Recent onset</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>12092</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>159</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>25</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>24</NumberOfSubjectsResponded>
                            <ResponseFrequency>96</ResponseFrequency>
                            <AssayComments>Using a dimeric,  branched,  MAP presented form of the epitope, a 96% sensitivity is obtained for detection of anti-hepatitis Abs in infected individuals. Positive threshold is considered as 2SD above the media signal from 10 normal human sera. A good correlation was seen between ELISA and SPR analysis. Similar results were obtained with the linear epitope,  while the use of a tetrameric form yielded less sensitivity, which is attributed to interchain aggregation on the biosensor chip due to its high content of beta-sheet structure.  The peptide was prepared on a MAP at a density of 2 peptides per MAP molecule, and immobilized in a biosensor chip. 100 microliters 1/100 diluted individual sera was added to the chip at a 10 microliter /min flow rate.The carrier consisted of MAP2.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FWRGDLVFDFQV</LinearSequence>
                                        <StartingPosition>110</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAR01186.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12092</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Multi-Antigenic Peptide (MAP, branched)</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

